<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn></journal-meta><article-meta><article-id pub-id-type="pmid">8260371</article-id><article-id pub-id-type="pmc">1968639</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>A phase-III study of recombinant interleukin 2 and 5-fluorouracil chemotherapy in patients with metastatic colorectal cancer.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hamblin</surname><given-names>T. J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sadullah</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Williamson</surname><given-names>P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Stevenson</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Oskam</surname><given-names>R.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Palmer</surname><given-names>P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Franks</surname><given-names>C. R.</given-names></name></contrib></contrib-group><aff>Royal Bournemouth Hospital, UK.</aff><pub-date pub-type="ppub"><month>12</month><year>1993</year></pub-date><volume>68</volume><issue>6</issue><fpage>1186</fpage><lpage>1189</lpage><abstract><p>Sixteen patients with metastatic colorectal cancer have been treated with a regimen involving an 120 h continuous infusion of rIL-2, 18 x 10(6) iu m-2 day followed by three injections of 5FU 600 mg m-2 at weekly intervals. Entry criteria included no previous chemotherapy, ambulatory performance status, and a measurable lesion. In most cases side effects were easily manageable and only one patient required transfer to an intensive care unit with the capillary leak syndrome. In three patients persistent hypotension was found to be unrelated to treatment with rIL-2, being caused respectively by a line infection, pulmonary embolus, and bowel perforation. This last proved a fatal complication. Five patients (33%; [95% confidence limits, 11.8%-61.6%]) achieved a partial response, and two non-responders later achieved a partial response when treated with weekly 5FU. This regimen is currently being evaluated in a phase-III randomised controlled trial.</p><sec sec-type="scanned-figures"><title>Images</title><fig id="F1"><label>Figure 1</label><graphic xlink:href="brjcancer00202-0144-a" xlink:role="1188"/></fig></sec></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00202-0142.tif" xlink:title="scanned-page" xlink:role="1186" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00202-0143.tif" xlink:title="scanned-page" xlink:role="1187" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00202-0144.tif" xlink:title="scanned-page" xlink:role="1188" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00202-0145.tif" xlink:title="scanned-page" xlink:role="1189" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

